Narsoplimab
mAbapprovedOrphan Drug FDA
Approved
Dec 23, 2025
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02222545)
Timeline
Indications
Approved for
Mechanism of action
Mannan-binding lectin serine protease 2 inhibitor
Approval history
- approvedDec 23, 2025
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298195 ↗
Also known as
- oms721
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05855083 | Phase 2 | May 1, 2023 | Omeros Corporation |
| NCT03608033 | Phase 3 | Feb 16, 2018 | Omeros Corporation |
| NCT03205995 | Phase 3 | Feb 23, 2017 | Omeros Corporation |
| NCT02682407 | Phase 2 | Feb 1, 2016 | Omeros Corporation |
| NCT02355782 | N/A | Jan 28, 2015 | Medical University of Lodz |
| NCT02222545 | Phase 2 | Aug 1, 2014 | Omeros Corporation |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Omeros Corporation | For profit | 5 | 5 | 2 | 2014 |
| Medical University of Lodz | Academic/Hospital | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1